Holen Sie sich die Stockscreener-App
3.65
2.67%
-0.10
Handel nachbörslich:
3.75
0.10
+2.74%
Schlusskurs vom Vortag:
$3.75
Offen:
$3.73
24-Stunden-Volumen:
70,888
Relative Volume:
0.74
Marktkapitalisierung:
$31.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.69M
KGV:
-1.5665
EPS:
-2.33
Netto-Cashflow:
$-3.81M
1W Leistung:
-4.95%
1M Leistung:
-13.30%
6M Leistung:
+32.73%
1J Leistung:
+58.70%
1-Tages-Spanne:
$3.61
$3.80
1-Wochen-Bereich:
$3.50
$4.0326
52-Wochen-Spanne:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Firmenname
Lixte Biotechnology Holdings Inc
Sektor
Branche
Telefon
310 203 2902
Adresse
433 PLAZA REAL, BOCA RATON
Vergleichen Sie LIXT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.65 | 32.64M | 0 | -4.69M | -3.81M | -2.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
Should I hold or sell Lixte Biotechnology Holdings Inc. stock in 2025Weekly Investment Summary & Accurate Technical Buy Alerts - ulpravda.ru
How Lixte Biotechnology Holdings Inc. stock compares to growth peers2025 Momentum Check & Target Return Focused Picks - ulpravda.ru
Can Lixte Biotechnology Holdings Inc. (8640) stock ride next bull market cycleQuarterly Market Review & Technical Buy Zone Confirmation - ulpravda.ru
Will Lixte Biotechnology Holdings Inc. (8640) stock beat revenue estimatesFed Meeting & Low Risk Entry Point Tips - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - Yahoo Finance
Lixte Biotechnology Expands Ovarian Cancer Trial with MD Anderson and GSK - citybuzz -
Will Lixte Biotechnology Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & AI Driven Stock Reports - ulpravda.ru
Lixte Biotechnology files to sell 5.26M shares of common stock, warrants - MSN
How strong is Lixte Biotechnology Holdings Inc. Equity Warrant stock revenue growth2025 Trade Ideas & Entry Point Strategy Guides - ulpravda.ru
Lixte Biotechnology announces new registered direct offering - MSN
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - financial-news.co.uk
Breakout Zone: Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Weekly Recap & Real-Time Market Sentiment Reports - ulpravda.ru
Can Lixte Biotechnology Holdings Inc. stock continue upward trendEarnings Forecast Updates & High Yield Trading Growth - ulpravda.ru
Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - Digital Journal
LIXTE Biotechnology Advances Novel Cancer Treatment Platform Through Clinical Trials and Strategic Moves - citybuzz -
Lixte Biotechnology Holdings Secures $4.3 Million in Registered Direct Offering to Advance Cancer Drug Development - citybuzz -
About Us | Oil & Gas JournalLIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’ - FinancialContent
About Us - FinancialContent
Will Lixte Biotechnology Holdings Inc. (8640) stock deliver compounding returns2026 world cup usa national team quarterfinals young talents transition play winner prediction breakdown - ulpravda.ru
Aug Decliners: Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsInsider Buying & Weekly Momentum Stock Picks - moha.gov.vn
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuation2026 world cup usa national team qualification midfield engines transition play winner prediction preview - ulpravda.ru
What analysts say about Lixte Biotechnology Holdings Inc 8640 stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
What analysts say about SBCWW stockTechnical Breakout Signals & Free Wealth Planning Blueprints - earlytimes.in
Should You Add Aster DM Healthcare Limited Stock to Your Portfolio NowResistance Breakout Alerts & Minimal Capital Growth - earlytimes.in
Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks
Price Clustering Detected in Anupam Finserv Limited StockLong-Term Investment Plans & Low Risk High Yield - bollywoodhelpline.com
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit Strategies & Low Entry Investment Portfolio - Bollywood Helpline
LIXTE expands clinical trial for ovarian cancer treatment By Investing.com - Investing.com Australia
Lixte Expands LB-100 Ovarian Cancer Trial Collaboration - TipRanks
Lixte expands LB-100 ovarian cancer trial collaboration - MSN
Key facts: Lixte Biotechnology secures $4.3M funding; expands cancer collaboration - TradingView — Track All Markets
LIXTE expands clinical trial for ovarian cancer treatment - Investing.com
Lixte Biotechnology Holdings expands collaboration with University of Texas MD Anderson Cancer Center & GSK for LB-100 - marketscreener.com
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - InvestorNews
Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering - Investing.com Nigeria
Lixte Biotechnology Announces New Registered Direct Offering - TipRanks
Lixte Biotechnology Signs Multiple Material Agreements - TradingView — Track All Markets
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering By Investing.com - Investing.com South Africa
Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com
Lixte Biotechnology stock falls after $4.3 million direct offering By Investing.com - Investing.com Canada
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering - The Manila Times
Will Lixte Biotechnology Holdings Inc. stock keep outperforming rivalsJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Whale Trades: Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyMarket Growth Report & Entry and Exit Point Strategies - Улправда
Profit Recap: What sentiment indicators say about Lixte Biotechnology Holdings Inc stockJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - moha.gov.vn
Can Lixte Biotechnology Holdings Inc. Equity Warrant stock deliver consistent earnings growthPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
What Wall Street predicts for Lixte Biotechnology Holdings Inc. Equity Warrant stock pricePortfolio Return Report & Daily Profit Maximizing Trade Tips - Улправда
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyTrade Risk Summary & Weekly Market Pulse Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesInsider Buying & Expert Approved Trade Ideas - Улправда
Finanzdaten der Lixte Biotechnology Holdings Inc-Aktie (LIXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):